Further experiments need to be conducted to verify the mechanism of MYD88 in the development of TME of gliomas, which might provide a new target gene and pathway in the treatment as an optional therapy combined with traditional and immunotherapy methods. The gene discussed is MYD88; the disease is central nervous system cancer.